Capability study · no client named
Shortening medical review without cutting corners
In life sciences commercial operations, medical, legal and regulatory review governs how fast anything reaches the field. Most attempts to speed it up target the reviewers. That rarely works, because the reviewers are not the problem — the unit of review is.
01The constraint
One claim changes, and the whole asset goes back through review
When an asset is reviewed as a single monolithic artefact, changing one claim re-triggers review of everything around it. A detail aid, an e-mailer and a leave-behind leaflet carrying the same approved claim are each reviewed independently, three times, by the same people.
02The change
Review the component, assemble the asset
Content is decomposed into components — a claim, a data visual, a safety statement — each reviewed once and versioned. Assets are then assembled from pre-approved components, so only genuinely new material enters review. Nothing is approved that was not approved before; it is simply not re-approved unnecessarily.
03What it takes
The technology is the straightforward part
A component taxonomy the medical team actually accepts, a digital asset management system that can hold approval state at component level, and review workflow that understands assembly. The taxonomy agreement is the hard part, and it is an organizational negotiation rather than an engineering task.
04Why it holds
It reduces review volume, not review rigour
This is the reason the change survives contact with a regulator and with the medical team. Nothing about the standard moves. What moves is how many times the same approved sentence is put in front of someone for approval again.
No client is named, no engagement is described and no figures appear here, because none has been approved for publication. What is above is method, and it is stated in full so it can be argued with.
